Vienna, Austria — November 25, 2025 — Leads & Copy — Lexogen, a Vienna-based biotech firm specializing in RNA transcriptomics technologies and services, has completed a large-scale data generation project with Ochre Bio, producing comprehensive functional genomics datasets from primary human hepatocytes. The project encompassed over 120,000 samples, assessed using Lexogen’s extraction-free, high-resolution gene expression profiling platform and NGS Services.
Ochre Bio, a biotechnology company, focuses on developing RNA medicines for chronic liver diseases that are currently under-treated. They build and integrate extensive human liver data, including proprietary gene perturbation and disease atlases, to make causal pathway predictions for target discovery and to facilitate the development of RNA therapies. Ochre’s proprietary OBELiX software enables the interrogation of gene biology in human cells, tissue, and whole livers, and it provides an AI-driven discovery engine for target prioritization.
High-fidelity RNA-Seq data is foundational for Ochre’s human discovery platform. Lexogen NGS Services has been a trusted long-term sequencing partner to Ochre Bio, delivering high-quality RNA-Seq data from various sample inputs, including bio-banked FFPE to micro-organ and primary hepatocyte samples at scale and on time.
Lexogen NGS Services operates in accordance with cGLP and primarily relies on proprietary Lexogen technologies, which are designed, developed, and manufactured under ISO 13485 in Vienna, Austria. Their expert teams provide state-of-the-art, streamlined, and customizable workflows to deliver the best results across all sample types, including the most challenging. Lexogen’s proprietary THOR and pooling technologies enable extraction-free RNA-Seq, high consistency, and resolution at scale.
Quin Wills, Founder and CEO of Ochre Bio, stated that with more than 120,000 samples derived from primary human hepatocytes, rigorous data quality and cross-sample consistency become essential for interpretability in AI-driven target discovery. He added that high-fidelity sequencing data, standardized processing, and reproducible assay performance enable machine-learning models to separate true biological signals from technical noise. Lexogen’s proprietary THOR technology and expert RNA-Seq service has delivered outstanding data at a large scale, enabling better target predictions in the future.
Stephane Barges, CEO of Lexogen, said that the entire Lexogen team strives to deliver high-quality services at scale for their customers and industry partners. He noted that delivering reliable, accurate data is central to their work, and they are committed to meeting the highest standards throughout every step of the process. He also stated that by focusing on quality and consistency, they aim to support their partners in advancing their discoveries and accelerating innovation. Lexogen’s mission extends beyond, as they are deeply motivated to support researchers and companies developing therapies and diagnostic tools that improve patient lives, and they are grateful that their work can play even a small part in contributing to better healthcare for everyone.
For nearly 20 years, Lexogen has offered comprehensive solutions for transcriptome analysis and RNA sequencing, including kits, reagents, bioinformatics, and services (CRO). Lexogen’s products are designed and manufactured in Vienna, Austria, and sequencing services are also delivered from Vienna. The company is ISO 9001 and 1385 certified, and all services are performed in compliance with cGLP and GDPR.
For additional information, visit Lexogen’s website: www.lexogen.com and follow @lexogen.
Contact:
Email: info@lexogen.com
Tel.: +43 1 345 1212
Source: Lexogen
